NASDAQ: DCTHDelcath Systems Inc Stock
$12.20+0.20 (+1.67%)
Updated Apr 29, 2025
DCTH Price
$12.20
Fair Value Price
N/A
Market Cap
$407.52M
52 Week Low
$5.15
52 Week High
$16.97
P/E
-13.12x
P/B
5.93x
P/S
9.23x
PEG
N/A
Dividend Yield
N/A
Revenue
$37.21M
Earnings
-$26.39M
Gross Margin
83.4%
Operating Margin
-71.26%
Profit Margin
-70.9%
Debt to Equity
0.11
Operating Cash Flow
-$19M
Beta
0.86
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
DCTH Overview
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. The firm's lead candidates, Melphalan Hydrochloride for Injection and the Delcath Hepatic Delivery System are designed to administer high-dose chemotherapy to the liver while controlling side effects. The company was founded in 1988 and is based in Queensbury, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DCTH's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
DCTH
Ranked#42 of 107
Ranked#42 of 107
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.56 | A | |
| $22.55 | A | |
| $14.22 | A |
Be the first to know about important DCTH news, forecast changes, insider trades & much more!
DCTH News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DCTH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DCTH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DCTH is poor value based on its book value relative to its share price (5.93x), compared to the US Medical Devices industry average (3.95x)
P/B vs Industry Valuation
DCTH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DCTH due diligence checks available for Premium users.
Valuation
DCTH fair value
Fair Value of DCTH stock based on Discounted Cash Flow (DCF)
Price
$12.20
Fair Value
-$3.80
Undervalued by
421.33%
DCTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DCTH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13.12x
Industry
37.36x
Market
29.19x
DCTH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.93x
Industry
3.95x
DCTH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DCTH's financial health
Profit margin
Revenue
$15.1M
Net Income
-$3.4M
Profit Margin
-22.5%
DCTH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DCTH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$76.6M
Liabilities
$7.8M
Debt to equity
0.11
DCTH's short-term assets ($73.76M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DCTH's short-term assets ($73.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DCTH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DCTH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.0M
Investing
-$15.2M
Financing
$40.4M
DCTH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DCTH vs Medical Device Stocks
Delcath Systems Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.